

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오약품협회, 2024.01.09.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.01.01.~2024.01.07.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 56건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06191796	Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)	Drug: zanzalintinib Drug: AB521 Biological: Nivolumab	Exelixis Arcus Biosciences, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06191796&rank=1
NCT06090864	ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells	Drug: Chemotherapy Biological: Cell infusion	UNC Lineberger Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06090864&rank=1
NCT06027086	DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)	Drug: Durvalumab Drug: DRP-104	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Dracen Pharmaceuticals, Inc. Fibrolamellar Cancer	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06027086&rank=1
NCT05687721	Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer	Drug: copanlisib Drug: Avelumab	VA Office of Research and Development Bayer	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05687721&rank=1
NCT05159453	Dose Response Study of Transdermal Human Insulin in Patients	Biological: Human Insulin Device: Finger-actuated, Metered Pump Sprayer	Transdermal Delivery Solutions Corp Langford Research Institute, Inc.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05159453&rank=1
NCT04731259	Study to Evaluate the Safety of ATR-04	Drug: ATR-04 Other: Placebo	Azitra Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT04731259&rank=1
NCT03811886	Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma	Drug: Natalizumab	Case Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT03811886&rank=1
NCT06162221	Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC	Drug: RMC-6291 Drug: RMC-6236 Drug: Pembrolizumab Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed	Revolution Medicines, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06162221&rank=1
NCT06069778	Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma	Drug: BNT321 Dose Level 1 Drug: BNT321 Dose Level 2 Drug: mFOLFIRINOX Drug: BNT321 RP2D	BioNTech SE	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06069778&rank=1
NCT06193174	Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)	Drug: C134 Re-Administration	University of Alabama at Birmingham	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT06193174&rank=1
NCT06175000	Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response	Procedure: Cognitive Assessment Biological: Obinutuzumab Other: Quality of Life Assessment	Providence Health & Services	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06175000&rank=1
NCT06156241	Stem Cell Study for Long COVID-19 Neurological Symptoms	Biological: Stem Cell	Charles Cox CBR Systems, Inc. The University of Texas Health Science Center, Houston	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT06156241&rank=1

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 미국 56건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06118372	Recombinant vWF Concentrate and ECMO	Drug: Recombinant von Willebrand Factor	University of Virginia	Phase 1	https://clinicaltrials.gov/study/NCT06118372
NCT06113809	Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)	Drug: Palbociclib Drug: Pembrolizumab	Mohammed Milhem University of Iowa	Phase 1	https://clinicaltrials.gov/study/NCT06113809
NCT06105931	Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes	Biological: Hyperinsulinemic-euglycemic clamp Other: High Fat Mixed Meal Tolerance Test	Yale University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	https://clinicaltrials.gov/study/NCT06105931
NCT06100913	Immunology of Ebola Vaccine	Biological: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV-G-Δ)	Emory University Washington University School of Medicine Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/study/NCT06100913
NCT06097832	Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis	Biological: NXC-201 CAR-T	Nexcella Inc.	Phase 1	https://clinicaltrials.gov/study/NCT06097832
NCT06071624	Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR) as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.	Biological: CD4CAR	Huda Salman iCell Gene Therapeutics The Leukemia and Lymphoma Society Indiana University	Phase 1	https://clinicaltrials.gov/study/NCT06071624
NCT06068543	Reducing Frailty for Older Cancer Survivors Using Supplements II	Drug: Epigallocatechin-3-Gallate (EGCG) Drug: Microcrystalline cellulose (MCC) Dietary Supplement: Ascorbic Acid (Vitamin C)	University of Rochester	Phase 2	https://clinicaltrials.gov/study/NCT06068543
NCT06067776	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	Biological: Cetuximab Drug: Osimertinib Drug: Tucatinib	Jonathan Riess National Cancer Institute (NCI) University of California, Davis	Phase 1	https://clinicaltrials.gov/study/NCT06067776
NCT06062875	Effects of TNF Blockade on Human BPH/LUTS	Drug: Adalimumab	NorthShore University HealthSystem National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	https://clinicaltrials.gov/study/NCT06062875
NCT06049082	A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency	Drug: KB408 (Nebulization)	Krystal Biotech, Inc.	Phase 1	https://clinicaltrials.gov/study/NCT06049082
NCT06048133	Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers	Drug: Gemcitabine Drug: Cisplatin Drug: Zimberelimab Drug: Quermliclustat	Nataliya Uboha Arcus Biosciences, Inc. Gilead Sciences University of Wisconsin, Madison Big Ten Cancer Research Consortium	Phase 2	https://clinicaltrials.gov/study/NCT06048133
NCT06043713	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	Drug: Bendamustine Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Multigated Acquisition Scan Procedure: Positron Emission Tomography Biological: T-cell Receptor-engineered T-cells	Fred Hutchinson Cancer Center Affini-T Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/study/NCT06043713

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 미국 56건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	Drug: Trilaciclib Drug: Pembrolizumab Drug: Gemcitabine Drug: Carboplatin	Wake Forest University Health Sciences Merck Sharp & Dohme LLC G1 Therapeutics, Inc.	Phase 2	https://clinicaltrials.gov/study/NCT06027268
NCT06017297	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: Tremelimumab Drug: Gemcitabine Drug: Cisplatin Procedure: Surgical Resection	Georgetown University AstraZeneca	Phase 2	https://clinicaltrials.gov/study/NCT06017297
NCT06014255	Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer	Drug: Enoblituzumab Other: Standard of Care	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins MacroGenics	Phase 2	https://clinicaltrials.gov/study/NCT06014255
NCT05996185	Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma	Drug: Mogamulizumab Drug: DA-EPOCH Protocol	Sethi Kyowa Kirin, Inc. Yale University	Phase 2	https://clinicaltrials.gov/study/NCT05996185
NCT05960578	Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study	Drug: Apalutamide Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Golimumab Procedure: Magnetic Resonance Imaging Procedure: PSMA PET Scan	University of Washington Janssen Scientific Affairs, LLC	Phase 2	https://clinicaltrials.gov/study/NCT05960578
NCT05925036	Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis	Drug: Mesenchymal stem cells Other: Placebo	VA Office of Research and Development	Phase 1	https://clinicaltrials.gov/study/NCT05925036
NCT05829239	ADI-PEG20, Obesity and Prediabetes	Biological: ADI-PEG20 Other: Placebo	Washington University School of Medicine Children's Discovery Institute Polaris Pharmaceuticals, Inc.	Phase 2	https://clinicaltrials.gov/study/NCT05829239
NCT05775471	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Enfortumab Vedotin Procedure: MR Urography Procedure: Nephroureterectomy Biological: Pembrolizumab	Jonsson Comprehensive Cancer Center Merck Sharp & Dohme LLC Seagen Inc.	Phase 2	https://clinicaltrials.gov/study/NCT05775471
NCT05726396	A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis	Drug: RMT Drug: Placebo	University of Minnesota	Phase 2	https://clinicaltrials.gov/study/NCT05726396
NCT05632315	PMT for MDRO Decolonization	Drug: PMT	University of Pennsylvania	Phase 2	https://clinicaltrials.gov/study/NCT05632315
NCT05539365	Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Biological: Alpha-type-1 Polarized Dendritic Cells Procedure: Biopsy Procedure: Computed Tomography Procedure: Leukapheresis Biological: Pembrolizumab Other: Quality-of-Life Assessment	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/study/NCT05539365
NCT05423197	Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma	Drug: 89Zr-panitumumab IV Drug: Panitumumab	Andrei Iagaru Stanford University	Phase 2	https://clinicaltrials.gov/study/NCT05423197

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 미국 56건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05330689	How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?	Biological: PRP injection dose (<5 billion platelets) Biological: PRP injection dose (between 5 and <10 billion platelets) Biological: PRP injection dose (between 10 and <20 billion platelets) Biological: PRP injection dose (20 billion or greater platelets) Other: Saline injection control	Vanderbilt University Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05330689
NCT05284214	Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors	Biological: Sargramostim Biological: Ipilimumab-containing therapy	Partner Therapeutics, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05284214
NCT05134740	(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).	Biological: TAA-specific CTLs	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05134740
NCT05079451	Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI	Drug: 3BNC117-LS Drug: 10-1074-LS	National Institute of Allergy and Infectious Diseases (NIAID) Rockefeller University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05079451
NCT05067595	Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease	Procedure: Colonoscopy Biological: Fecal Microbiota Transplantation Dietary Supplement: Nutritional Supplementation Other: Survey Administration	Fred Hutchinson Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05067595
NCT04715191	Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors	Genetic: CARE T cells Drug: Cytoxin Drug: Fludara	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04715191
NCT06152809	A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AML	Biological: Cytokine-Induced Memory-like Natural Killer Cells Biological: Interleukin-2 Drug: Venetoclax	Dana-Farber Cancer Institute The Leukemia and Lymphoma Society	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06152809
NCT06145035	Single or Repeated Intravenous Administration of umbilical Cord Mesenchymal sTrOm al Cells in Ischemic Cardiomyopathy	Biological: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)	Roberto Bolli University of Miami University of Texas United States Department of Defense University of Louisville	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06145035
NCT06056102	CAR-T Cell Therapy for Desensitization in Kidney Transplantation	Drug: Cyclophosphamide Biological: CART-BCMA Biological: huCART19 Drug: Fludarabine	National Institute of Allergy and Infectious Diseases (NIAID) University of Pennsylvania Clinical Cell and Vaccine Production Facility (CVPF)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06056102
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Drug: Carboplatin Drug: Tocilizumab	Kathy Miller Genentech, Inc. Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05846789
NCT06188208	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors	Drug: VVD-130850 Drug: Pembrolizumab	Vividion Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06188208
NCT05937152	A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy	Drug: Eptinezumab Drug: Placebo	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05937152

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 미국 56건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05469802	A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults	Biological: Purified Inactivated Zika Virus Vaccine (PIZV) Other: Placebo	Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05469802
NCT06071767	Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1	Biological: ChAdOx1.tHIVconsrv1 Biological: ChAdOx1.HIVconsrv62 Biological: MVA.tHIVconsrv3 Biological: MVA.tHIVconsrv4 Drug: Vesatolimod (VES) Drug: GS-5423 Drug: GS-2872 Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) University of Oxford Gilead Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06071767
NCT04046107	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	Biological: Cemiplimab	National Institute of Allergy and Infectious Diseases (NIAID) Regeneron Pharmaceuticals	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04046107
NCT06183931	Study of ALXN2220 Versus Placebo in Adults With ATTR-CM	Drug: ALXN2220 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06183931
NCT06119581	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C	Drug: LY3537982 Drug: Pembrolizumab Drug: Placebo Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed	Eli Lilly and Company Loxo Oncology, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06119581
NCT06179160	A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Drug: INCB161734 Drug: Cetuximab Drug: Retifanlimab	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06179160
NCT05776277	Ittamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury	Biological: Ittamiocel Other: Placebo	Cook MyoSite	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05776277
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

○ 영국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06045910	A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies	Drug: ALETA-001	Cancer Research UK Aleta BioTherapeutics	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06045910
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	Drug: Futibatinib Drug: Ivosidenib Drug: Zanidatamab Drug: Trastuzumab Drug: Neratinib Drug: Encorafenib Drug: Binimetinib Drug: Niraparib Drug: Cisplatin Drug: Gemcitabine	UNICANCER Cancer Research UK & UCL Cancer Trials Centre Belgian Group of Digestive Oncology National Cancer Institute, France Cancer Research UK Taiho Oncology, Inc. Servier Zymeworks Inc. Accord Healthcare, Inc. Pierre Fabre Medicament GlaxoSmithKline Research & Development Limited	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05615818

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 영국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06119581	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C	Drug: LY3537982 Drug: Pembrolizumab Drug: Placebo Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed	Eli Lilly and Company Loxo Oncology, Inc.	Phase 3	https://clinicaltrials.gov/study/NCT06119581
NCT06183931	Study of ALXN2220 Versus Placebo in Adults With ATTR-CM	Drug: ALXN2220 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/study/NCT06183931
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/study/NCT06079359
NCT05737628	First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228	Drug: BYON4228 + Rituximab	Byondis B.V.	Phase 1	https://clinicaltrials.gov/study/NCT05737628

○ 프랑스 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06192693	Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery	Drug: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution Drug: Capsulized placebo transfer containing dilution solution	Assistance Publique - Hôpital de Paris	Phase 3	https://clinicaltrials.gov/study/NCT06192693
NCT06038331	Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis	Biological: SclerFIX-IP	TBF Genie Tissulaire	Phase 2	https://clinicaltrials.gov/study/NCT06038331
NCT06037460	Tocilizumab discontinuation in Giant Cell Arteritis	Drug: Tocilizumab treatment Other: questionnaires Biological: Blood samples Procedure: 18FDG PET scan	Centre Hospitalier Universitaire Dijon	Phase 3	https://clinicaltrials.gov/study/NCT06037460
NCT06034262	Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis	Biological: SclerFIX-IP	TBF Genie Tissulaire	Phase 2	https://clinicaltrials.gov/study/NCT06034262

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06045195	Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma	Drug: Pembrolizumab	University of Cologne	Phase 2	https://clinicaltrials.gov/study/NCT06045195
NCT05727267	A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate	Biological: HEPLISAV B; TherVacB Biological: TherVacB	Universitätsklinikum Hamburg-Eppendorf German Center for Infection Research Medical Biometry and Epidemiology - Universitätsklinikum Hamburg Eppendorf Helmholtz Zentrum München Fraunhofer Gesellschaft Institute of Virology Helmholtz Zentrum München (HMGU) Klinikum der Universität München (LMU) Monipol Deutschland GmbH	Phase 1	https://clinicaltrials.gov/study/NCT05727267

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오약품협회, 2024.01.09.

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05690048	Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)	Drug: Fecal microbiota transfer Drug: Vancomycin Oral Capsule Drug: Atezolizumab + Bevacizumab Drug: Placebo Vancomycin Oral Capsule Drug: Placebo Fecal microbiota transfer	Michael Dill National Center for Tumor Diseases, Heidelberg German Cancer Research Center Heidelberg University University of Cologne Universitätsmedizin Mannheim University Hospital Heidelberg	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05690048
NCT06183931	Study of ALXN2220 Versus Placebo in Adults With ATTR-CM	Drug: ALXN2220 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06183931
NCT06119581	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C	Drug: LY3537982 Drug: Pembrolizumab Drug: Placebo Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed	Eli Lilly and Company Loxo Oncology, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06119581
NCT05056220	Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites	Drug: Human albumin Drug: sodium chloride	Aleksander Krag EASL - CLIF Consortium Odense University Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05056220
NCT06079359	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Drug: ALXN1850 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06079359

○ 중국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06188624	Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers	Drug: TQB2922 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06188624
NCT06183216	A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine	Biological: Sinovac PCV13 Biological: PREVNAR 13	Sinovac Research and Development Co., Ltd. Sinovac Biotech Co., Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06183216
NCT06170294	MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors	Drug: TCR-MAGE-A4 T-Cells	Peking University Shanghai Ming Ju Biotechnology Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06170294
NCT06166589	Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer	Drug: Zimberelimab Drug: Oxaliplatin Drug: S-1 Drug: Irinotecan	Shanghai Zhongshan Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06166589
NCT06157996	Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore	Drug: lenvatinib and tislelizumab plus CapeOX chemotherapy Drug: tislelizumab plus CapeOX chemotherapy	Nanfang Hospital, Southern Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06157996
NCT06148402	Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer	Drug: Fruquintinib plus camrelizumab and capecitabine	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06148402

해외 바이오의약품 임상 현황 ('24년 1월 1주)

한국바이오의약품협회, 2024.01.09.

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06119581	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C	Drug: LY3537982 Drug: Pembrolizumab Drug: Placebo Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed	Eli Lilly and Company Loxo Oncology, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06119581
NCT06183931	Study of ALXN2220 Versus Placebo in Adults With ATTR-CM	Drug: ALXN2220 Drug: Placebo	Alexion Pharmaceuticals, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06183931